Patent Assignment
Reel/Frame 023796/0417
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded: 2010-01-08
Received: 2010-01-15
Pages: 120
Assignor
PROCTER & GAMBLE COMPANY, THE
Executed: 2009-10-30
Assignee
WARNER CHILCOTT COMPANY, LLC
UNION STREET, KM1.1, FAJARDO, PRX, 00738, UNITED STATES
Covered Applications
(65)
METHODS OF TREATMENT FOR ULCERATIVE COLITIS
App. No. 12/309,930
→
CORTICOTROPIN RELEASING FACTOR 2 RECEPTOR AGONISTS
App. No. 12/605,718
→
BISPHOSPHONATE COMPOUNDS
App. No. 61/254,886
→
METHODS OF TREATMENT FOR ULCERATIVE COLITIS USING AMINOSALICYLATE
App. No. 12/376,168
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
App. No. 12/558,169
→
Methods And Kits For The Treatment Inhibition, And Maintenance Of Gastrointestinal Disorders
App. No. 12/491,522
→
CRYSTAL OF HYPOXIA INDUCIBLE FACTOR 1 ALPHA PROLYL HYDROXYLASE
App. No. 12/473,536
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
App. No. 12/467,430
→
Treatment Of Lower Urinary Tract Dysfunction With CB2-Receptor-Selective Agonists
App. No. 12/465,762
→
TREATMENT OF HEART FAILURE IN WOMEN
App. No. 12/465,467
→
THREE DIMENSIONAL COORDINATES OF HPTPBETA
App. No. 12/409,111
→
ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES
App. No. 12/338,271
→
COUPLING PROCESS FOR PREPARING QUINOLONE INTERMEDIATES
App. No. 12/258,480
→
LOW DOSAGE FORMS OF RISEDRONATE OR ITS SALTS
App. No. 12/183,336
→
LOW DOSAGE FORMS OF RISEDRONATE OR ITS SALTS
App. No. 12/183,359
→
Methods And Kits For The Treatment Inhibition And Maintenance Of Gastrointestinal Disorders
App. No. 61/076,207
→
VITAMIN D CONTENT UNIFORMITY IN PHARMACEUTICAL DOSAGE FORMS
App. No. 12/148,987
→
Compositions of azimilide dihydrochloride
App. No. 12/001,321
→
Method of treating menopausal women transdermally with testosterone
App. No. 11/974,069
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AN METHODS OF USE
App. No. 11/823,086
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
App. No. 11/821,846
→
HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
App. No. 11/821,868
→
PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE
App. No. 11/821,936
→
N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
App. No. 11/820,097
→
N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES
App. No. 11/820,099
→
PHARMACEUTICAL COMPOSITIONS THAT MODULATE HPTPBETA ACTIVITY
App. No. 11/787,535
→
ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
App. No. 11/784,094
→
BLISTER CARD
App. No. 29/285,645
→
COUPLING PROCESS FOR PREPARING QUINOLONE INTERMEDIATES
App. No. 11/728,342
→
HYDRIDE REDUCTION PROCESS FOR PREPARING QUINOLONE INTERMEDIATES
App. No. 11/728,341
→
MALATE SALTS, AND POLYMORPHS OF (3S,5S)-7-[3-AMINO-5-METHYL-PIPERIDINYL]-1-CYCLOPROPYL-1,4-DIHYDRO-8-METHOXY-4-OXO-3-QUINOLINECARBOXYLIC ACID
App. No. 11/728,343
→
CRYSTAL OF HYPOXIA INDUCIBLE FACTOR 1 ALPHA PROLYL HYDROXYLASE
App. No. 11/713,941
→
CORTICOTROPIN RELEASING FACTOR 2 RECEPTOR AGONISTS
App. No. 11/701,912
→
CORTICOTROPIN RELEASING FACTOR 2 RECEPTOR AGONISTS
App. No. 11/701,576
→
Method of treating menopausal women transdermally with testosterone
App. No. 11/606,815
→
COMPOSITIONS FOR REDUCING THE INCIDENCE OF DRUG INDUCED ARRHYTHMIA
App. No. 11/489,756
→
METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING CORTICOTROPIN RELEASING FACTOR RECEPTORS
App. No. 11/412,025
→
ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS, AND USES
App. No. 11/301,685
→
DOSAGE FORMS OF RISEDRONATE
App. No. 11/286,875
→
Compositions containing 5-amino-2-hydroxybenzoic acid and a reducing sugar
App. No. 11/218,132
→
N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES
App. No. 11/152,002
→
N-SULFONYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES
App. No. 11/151,897
→
CORTICOTROPIN RELEASING FACTOR 2 RECEPTOR AGONISTS
App. No. 11/121,612
→
DOSAGE FORMS OF BISPHOSPHONATES
App. No. 11/106,816
→
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
App. No. 11/096,457
→
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
App. No. 11/070,995
→
ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES
App. No. 11/003,588
→
PROCESS FOR CONTROLLING CRYSTAL STRUCTURE OF RISEDRONATE
App. No. 10/901,692
→
Kit for pharmaceutical use
App. No. 10/789,525
→
N-SULFONYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES
App. No. 10/703,067
→
N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES
App. No. 10/702,953
→
METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING CORTICOTROPIN RELEASING FACTOR RECEPTORS
App. No. 10/649,852
→
HPTPBETA AS A TARGET IN TREATMENT OF ANGIOGENESIS MEDIATED DISORDERS
App. No. 10/633,742
→
THREE DIMENSIONAL COORDINATES OF HPTPBETA
App. No. 10/634,027
→
PROCESS FOR PREPARING QUINOLONE ANTIBIOTIC INTERMEDIATES
App. No. 10/630,608
→
STORAGE CIRCUIT
App. No. 10/429,158
→
ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES
App. No. 10/392,476
→
CORTICOTROPIN RELEASING FACTOR 2 RECEPTOR AGONISTS
App. No. 10/317,252
→
CORTICOTROPIN RELEASING FACTOR 2 RECEPTOR AGONISTS
App. No. 10/317,251
→
CORTICOTROPIN RELEASING FACTOR 2 RECEPTOR AGONISTS
App. No. 10/315,964
→
PHARMACEUTICAL DOSAGE FORM WITH MULTIPLE COATINGS FOR REDUCED IMPACT OF COATING FRACTURES
App. No. 09/996,555
→
ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES
App. No. 09/929,943
→
METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING CORTICOTROPIN RELEASING FACTOR RECEPTORS
App. No. 09/799,978
→
Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
App. No. 09/771,825
→
PROCESS FOR MAKING GEMINAL BISPHOSPHONATES
App. No. 09/771,899
→